1. Home
  2. Clinical Topics
  3. Cardio-Pulmonary
  4. FDA approves Corifact for congenital Factor XIII deficiency
Cardio-PulmonaryClinical TopicsDrugs and DevicesHealthcare & TechnologyNewsWeb Exclusives

FDA approves Corifact for congenital Factor XIII deficiency

Share

The U.S. Food and Drug Administration has approved Corifact, the first product for preventing bleeding in people with congenital Factor XIII deficiency. Read more at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm243856.htm.

Leave a Reply

Your email address will not be published.

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts